Brolucizumab: is extended VEGF suppression on the horizon?

Subjects

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57–65.e5.

  2. 2.

    Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One. 2014;9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076243/

  3. 3.

    Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye. 2016;30:270–86.

  4. 4.

    Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med 2018;23:127–40.

  5. 5.

    Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 2016;100:914–7.

  6. 6.

    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. 2008;145:239–248.e5.

  7. 7.

    Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019;126:1141–54.

  8. 8.

    Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, et al. Double-masked, randomized, phase 2 evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in neovascular age-related macular degeneration. J Ocul Pharmacol Therapeutics. 2018;34:700–9.

  9. 9.

    Mojumder NI, Khanani AM. Retinal physician—the mechanism of the bi-specific antibody Faricimab. Retinal Phys. 2019. https://www.retinalphysician.com/issues/2019/march-2019/the-mechanism-of-the-bispecific-antibody-faricimab

  10. 10.

    Dugel PU, Koh A, Ogura Y, Jaffe G, Schmidt-Erfurth U, Brown D, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5.

  11. 11.

    Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD. Novartis. 2019. https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd

  12. 12.

    Gaudreault J, Gunde T, Flyod HS, Ellis J, Tietz J, Binggeli D, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:3025.

  13. 13.

    Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration. Ophthalmology. 2016;123:1080–9.

  14. 14.

    Tietz J, Spohn G, Schmid G, Konrad J, Jampen S, Maurer P, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor A for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56:1501.

  15. 15.

    Singerman LJ, Weichselberger A, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Invest Ophthalmol Vis Sci. 2015;56:4801.

  16. 16.

    Sharma A, Kumar N, Kuppermann BD, Francesco B, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye. 2019. http://www.nature.com/articles/s41433-019-0434-y

  17. 17.

    Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–304.

  18. 18.

    Regeneron Pharmaceuticals Inc. FDA approves EYLEA® (aflibercept) injection sBLA in wet age-related macular degeneration. Regeneron Pharmaceuticals Inc. 2019. https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-sbla-wet-age-related

Download references

Author information

Correspondence to Ashish Sharma.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Kumar, N., Kuppermann, B.D. et al. Brolucizumab: is extended VEGF suppression on the horizon?. Eye 34, 424–426 (2020). https://doi.org/10.1038/s41433-019-0582-0

Download citation

Further reading